147,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
74 °P sammeln
  • Broschiertes Buch

Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges…mehr

Produktbeschreibung
Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined.
Rezensionen
From the reviews: "Immunotherapy of Cancer provides in 28 chapters a comprehensive overview of experimental and clinical achievements in tumor immunology. Each chapter is designed to give the reader the scientific basis behind the discussed therapy and outline basic theory, as well as practical treatment applications. ... The book belongs to the successful series of publications Cancer Drug Discovery and Development from Humana Press. It will be of interest to clinicians and to laboratory cancer researchers ... ." (Cestmir Altaner, Neoplasma, Vol. 54 (2), March, 2007)